by Marisa Wexler, MS | Nov 6, 2025 | Myeloma News
Enrollment has begun in the second part of a clinical trial testing safusidenib, an experimental oral treatment, as a maintenance therapy for high-grade IDH1-mutant astrocytoma — an aggressive form of glioma. The study (NCT05303519) — sponsored by safusidenib’s...
by MM360 Staff | Nov 6, 2025 | Myeloma News
Source: Myeloma : nature.com subject feeds Post Content Read More
by Steve Bryson, PhD | Nov 5, 2025 | Myeloma News
Canada’s Drug Agency (CDA-AMC) has recommended that Canadian public drug plans cover the cost of the gynecological cancer therapy Elahere (mirvetuximab soravtansine) under certain conditions. The treatment, marketed by Abbvie, was approved by Health Canada in...
by MM360 Staff | Nov 5, 2025 | Myeloma News
Source: Pharmacy Times articles Post Content Read More
by Andrea Lobo | Nov 4, 2025 | Myeloma News
One-time use of CB-011, Caribou Biosciences’ off-the-shelf CAR T-cell therapy candidate, showed a manageable safety profile and resulted in lasting responses in adults with treatment-resistant or relapsed multiple myeloma. That’s according to the first data from the...
by Marisa Wexler, MS | Nov 4, 2025 | Myeloma News
The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to iopofosine I 131 — now being tested in young people in a clinical trial in North America — as a potential treatment for inoperable relapsed or refractory (hard-to-treat)...
